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INTRODUCTION
Prolactin (PRL) occurs in three isoforms, i.e. a monomericPRL {MW~23 kDa}, a big PRL {MW~50 kDa} and acomplex of monomeric prolactin and IgG known asmacroprolactin (MaPRL) or as "big, big PRL" {MW <100kDa}.1 Circulating total prolactin hormone in normal andpatients with increased prolactin levels mainly compriseof monomeric PRL (<85%) and MaPRL (less than 2%).MaPRL is biologically inert, as it is impermeable to thecapillary blood barrier due to its large molecular size butis measured in the prolactin assay leading to falselyelevated prolactin levels.2,3 However, in few cases of
hyperprolactinemia; MaPRL becomes the dominantform, as it has been reported from 10% to 45% inhyperprolactinemic patients.4-6
The polythylene glycol (PEG) precipitation is usedwidely in clinical laboratories performing prolactin assayto screen for MaPRL.2,3 PEG precipitation distinguishespatients with true hyperprolactinemia, which is due toincrease of bioactive monomeric PRL, from those withMaPRL, in which monomeric prolactin is normal inconcentrations. Inability of laboratories to performPEG precipitation leads to overreporting of hyper-prolactinemia and consequent over investigation of thepatient by treating physicians.4,5
PEG precipitation and analysis for MaPRL andmonomeric prolactin of all samples with hyper-prolactinemia was started at the laboratory as a qualityimprovement initiative. This study was conducted todetermine the frequency of MaPRL in patients withincreased total prolactin and its impact on clinical andfinancial outcome.
METHODOLOGY
A retrospective cross-sectional study was carried out atSection of Clinical Chemistry, Department of Pathology
Journal of the College of Physicians and Surgeons Pakistan 2018, Vol. 28 (2): 93-97 93
ORIGINAL ARTICLE
Frequency of Macroprolactin in Hyperprolactinemia
Noreen Abbas Sherazi1, Mirza Zain Baig2 and Aysha Habib Khan3
ABSTRACT
Objective: To determine the frequency of Macroprolactin (MaPRL) in patients with increased total prolactin and its clinicaland financial impact.Study Design: Cross-sectional study.Place and Duration of Study: Section of Clinical Chemistry, Department of Pathology and Laboratory Medicine, The AgaKhan University Hospital, Karachi, from March to May 2015.Methodology: Patients with high total prolactin were screened by polyethylene glycol (PEG) precipitation for determinationof MaPRL. Clinical history, imaging work-ups, and cost incurred in further investigations were collected by telephonic interviewafter verbal consent. Patients were stratified into true hyperprolactinemia and macroprolactinemia after PEG treatment,based on monomeric prolactin levels. Medical records of cases registered with AKUH were reviewed to confirm the diagnosis.Results: Two hundred and thirty-nine patients were identified with high prolactin levels. Macroprolactinemia was identifiedin 145 (60.7%) and true hyperprolactinemia in 94 (39.3%) patients. Galactorrhea was significantly more in truehyperprolactinemic females (p=0.022), followed by visual disturbances (p=0.01) and headache (p=0.006). Moreover, asmajority of population were females, the clinical features in the macroprolactinemia group as compared to truehyperprolactinemic group were mostly related to non-pituitary causes like drug intake [42.5% (54) vs. 37% (30)], heatintolerance due to thyroidal illness [41.7% (53) vs. 38.3% (31)] and surgery [26.8% (34) vs 22.2% (18)] in females. Furtherradiological workup (MRI, CT) were conducted in 35 (37.2%) patients with true hyperprolactinemia. Twenty-one (60%) ofthe patients were confirmed to have pituitary adenomas. In eight (5.5%) patients with MaPRL, only one had pituitary micro-adenoma on radiological workup. Total cost impact on the basis of investigations, was significantly higher in the groupundergone imaging, despite 7 out of 8 individuals found to have normal imaging results. The median total cost in truehyperprolactinemic group undergone imaging was Rs. 4370 (IQR=2412.5, 22850) as compared to macroprolactinemicgroups; Rs. 3,250 (IQR=2150, 4278). There was significant difference in the cost burden of both the groups (p <0.001).Conclusion: High frequency of MaPRL was identified in patients with hyperprolactinemia. Screening with PEGprecipitation in hyperprolactinemic sera is simple and cost-effective.
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and Laboratory Medicine, The Aga Khan University,Karachi. The study was approved by the Ethical ReviewCommittee of The Aga Khan University Hospital.Patients' sera having high total prolactin levels (>25-200ng/ml in females and >15-200 ng/ml in males) werescreened by PEG precipitation for MaPRL determination.Patients were contacted by telephone and those whogave verbal consent, were interviewed about clinicalhistory, imaging workups and cost incurred in furtherinvestigations. Medical records of cases registered atAKUH were reviewed to confirm the diagnosis.
Serum samples with increase prolactin concentrationwere mixed with an equal volume of 25% PEG in saline,and incubated for 10 mins at room temperature. Themonomeric PRL level in the supernatant was quantifiedby enzyme-amplified chemiluminescent immunoassay(ECLIA) on Immulite 2000, from Siemens, Germany.
Analytical sensitivity of the assay was 0.5 ng/mL. AnIntra-assay coefficient of variation (CV) at the PRLconcentration of 11.9 ng/mL was 4.8% and inter-assayCV at the concentration of 22.3 ng/mL was 4.0%.Reference ranges used in the laboratory were 1.9-25.0ng/mL for women and 2.5-17.0 ng/mL for men.
The reproducibility of the PEG precipitation procedurewas monitored by inclusion of control sera in each
assay. Absolute levels of monomeric prolactin in seraafter PEG precipitation were used for reference rangei.e. 3.6-12.4 ng/ml in males and 4-18.5 ng/ml in females.7
The data was analyzed on SPSS (version 21.0).Macroprolactinemia accounts for up to 15% to 30% infrequency so for sample size calculation, taking 95%confidence interval with 5% type 1 error, 196 number ofpatients were required to achieve the target population.Two hundred and thirty-nine patients were recruited forbetter spread of data. Frequencies and percentages forcategorical variable, mean and standard deviation (SD)for discrete or continuous variables and for non-parametric data, median with interquartile range werecalculated. Patients were stratified under macro-prolactinemia group and true hyperprolactinemia group,according to monomeric reference range after PEGtreatment. Cost comparison between both truehyperprolactinemia and those with MaPRL wereperformed by mean expenditure in performing imagingstudies. The Chi-square test used for categoricalvariables; in case sample size or frequency found lessthan <5 then Fishers' exact test was employed forcontinuous variables. Additionally, for non-parametricdata, Mann-Whitney and Kolmogorov-Smirnov testswere used to check normality of data. P-value <0.05 wastaken as level of significance in analysis.
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Figure 1: Consort diagram of study participants. The flow of patients enrolled, screened and imaged is shown in accordance to the CONSORT statement.
RESULTS
Figure 1 shows the total number of patients tested forserum prolactin at the Section of Clinical Chemistry,Department of Pathology and Laboratory Medicineduring the study period, with breakup of those screenedand enrolled in the study.
Three hundred and fifty patients, out of 591 with PRLlevels between normal range and till 200 ng/ml, werescreened for MaPRL by PEG precipitation. Out of these,239 gave informed consent and provided the clinicaldetails. Median age of the patients was 28 years,(IQR=24, 35) and male/female ratio was 31/208, withfemale preponderance. MaPRL was present in 60.7%(n=145) of hyperprolactinemic patients. The monomericPRL levels are significantly different (p <0.001) from26.7 ng/ml (IQR=21.2, 44.9) to 12.9 ng/ml (IQR=9.8,15.1) in true hyperprolactinemia and macroprolactinafter PEG precipitation.
Table I compares the demographic and biochemical detailsof patients with true hyperprolactinemia and macro-prolactinemia. Total prolactin was significantly higher(p <0.001) in patients with true hyperprolactinemia ascompared to patients with MaPRL and this differencewas maintained after treatment with PEG. There wasalso significant difference in the cost burden of both thegroups (p <0.001). The median total cost in true hyper-prolactinemic group undergone imaging was Rs. 4,370(IQR=2412.5, 22850) as compared to macroprolactinemicgroup was Rs. 3,250 (IQR=2150, 4278).
The indications for testing of prolactin were diverse andvaried between males and females (Figures 2a and 2b).Overall in females, predominantly menstrual disturbances,infertility, oligomenorrhea were the main indications fortesting followed by heat intolerance, obesity, headache,cold intolerance, visual disturbance and galactorrhea.
While in males, indications for testing were predominantlyheat intolerance, visual disturbance, infertility andobesity followed by headache, cold intolerance andgalactorrhea. Monomeric and MaPRL levels in patientswith hyperprolactinemia did not differ when comparedwith clinical presentation in either males or females.Upon stratification, Galactorrhea was significantly morein true hyperprolactinemic females    (p=0.022), followedby visual disturbances (p=0.01) and headache(p=0.006). Moreover, as majority of population werefemales, the clinical features in the macroprolactinemiagroup as compared to true hyperprolactinemic groupwere mostly related to non-pituitary causes like drugintake [42.5% (54) vs. 37% (30)], heat intolerance due tothyroidal illness [41.7% (53) vs. 38.3% (31)] and surgery[26.8% (34) vs. 22.2% (18)] in females.
Imaging studies (MRI, CT) were conducted in 35(37.2%) patients with true hyperprolactinemia. However,only 8 (5.5%) patients with MaPRL were directed forfurther imaging. Statistically significant difference(p <0.001) in financial impact was seen between the twogroups. Among the 35 patients, who underwent MRI/ CTscan, medical records showed that 21 (60%) of thepatients were confirmed to have pituitary adenomas.Whereas, in the group of patients with hyper-prolactinemia due to MaPRL, only one patient wasidentified with pituitary microadenoma as shown in Table I.
Macroprolactin screening by PEG precipitation
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Table I: Comparison of demographic, biochemical and expenses inpatients with true hyperprolactinemia due to MaPRL screenedat Aga Khan University Hospital Clinical Laboratories (n=239).
Variables True Hyperprolactinemia MacroPRL p-value
(n=94) (n=145)
Age (years) 28 (IQR=24, 35) 28 (IQR=24, 35) 0.846
Gender
Male   13 (13.8%) 81 (86.2%) 0.750
Female  18 (12.4%) 127 (87.6%)
Marital Status
Married    68 (72.3%) 118 (81.4%) 0.101
Single 26 (27.7%) 27 (18.6%)
Total Prolactin (ng/ml) 49.3 (IQR=35.4,81.9) 27 (IQR=24,32) <0.001**
Monomeric Prolactin 26.7 (IQR= 21.2,44.9) 12.9 (IQR= 9.8,15.1) <0.001**(ng/ml)
Radiological (MRI+CT) 35 (37.2%) 8 (5.5%)
Adenoma detected 21 1 <0.001**
Adenoma not detected 14 7
Total cost (PKR) 4370 3250 <0.001**
(IQR=2412.5, 22850) (IQR=2150, 4278)
**Highly significant;   *Significant.
Figure 2: Indications for screening of patients for hyperprolactinemia andfrequency comparison between true hyperprolactinemia and patients withMaPRL.
DISCUSSION
A high frequency of patients with hyperprolactinemiawas identified due to MaPRL in our patient population.Out of the 145 patients diagnosed with MaPRL, 1 out of8 patients who underwent MRI or CT scan wereidentified with microadenoma on CT scan. Previousreports also described minor CT or MRI scanabnormalities consistent with the presence of amicroadenoma in macroprolactinemic patient. Consistentwith this observation, abnormal pituitary CT scans 21%vs. 75% are reported in macroprolactinemic and truehyperprolactinemic patients, respectively. Such patientsneed follow-up scans and monitoring of pituitarymicroadenoma, as surgical intervention is needed ingrowing microadenomas/macroadenomas.10-12
MaPRL is the complex of monomeric prolactin attachedto IgG, which results in increased size of prolactinmolecule and hinders its renal clearance leading toincreased levels of total PRL. As shown in this study, it isdifficult to differentiate between true hyperprolactinemiaand that due to MaPRL by clinical judgment alone; asmost of the patients with MaPRL were also symptomatic.The absence of MaPRL screening by laboratoriesperforming prolactin assay leads to over investigatingpatients with imaging studies and; hence, increase costof management. High frequency of MaPRL is identifiedin this study and as reported by other studies also,menstrual disturbances, infertility and galactorrhearemains the most common clinical findings as mentionedin Table II.
Cost-effectiveness of macroprolactin screening isalready established in literature and mean cost washigher in normal macroprolactin individuals' undergoneimaging, which was cost burden due to unnecessaryinvestigations.13-15 As seen in our study, the meanexpenditure was much less in MaPRL group, who didnot need to go for imaging after PEG screening.
It is important that clinical laboratories performingprolactin testing should screen for MaPRL in allhyperprolactinemic sera. It is equally important thatclinicians involved in managing these patients should beaware of this potential diagnostic pitfall and insist onmacroprolactin screening. However, the results shouldbe evaluated in detailed clinical context as few patientswith MaPRL can have microadenomas, which are
identified on MRI or CT scan and need careful monitoringand follow-up.
PEG precipitation is a simple, economical and a rapidmethod for the detection of MaPRL. Screening forMaPRL in all prolactin assays above reference range isa recommended good laboratory practice by mostorganizations. Method specific reference intervals arebetter than percent recovery method.7,8,10
CONCLUSION
High frequency of MaPRL was identified in patients withhyperprolactinemia. Screening with PEG precipitation inhyperprolactinemic sera is simple and cost-effective.
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